IL-15 fusion protein and mRNA sequence and application thereof
By designing the interleukin 15 fusion protein RLI-mono-hFc and its mRNA sequence, combined with the delivery of lipid nanoparticles, the problem of insufficient biological activity of existing IL15 superagonists was solved, and a significant tumor suppression effect was achieved.
Patent Information
- Application Number
- CN202410538353.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-06
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-08
AI Technical Summary
The existing IL15 superagonists have shortcomings in their biological activities, which are difficult to effectively inhibit tumor growth, and their construction process is complex and inefficient.
A interleukin 15 fusion protein was designed, including IGHE signal peptide, IL-15 receptor Rαsushi domain, linking peptide and Fc monomer CH2 and CH3 segments, and optimized its composition by mRNA sequence to form the RLI-mono-hFc protein. Combined with lipid nanoparticles as delivery vehicles for the treatment of tumors.
RLI-mono-hFc protein significantly improves biological activity, can induce cell proliferation at lower concentrations, and effectively inhibits tumor growth, showing strong anti-tumor potential.
Smart Images

Figure BDA0004820313380000041 
Figure BDA0004820313380000051 
Figure BDA0004820313380000061
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, relates to mRNA drug sequence design, and specifically relates to an IL-15 fusion protein, an mRNA sequence and applications thereof. Background Art
[0002] Cytokines are a class of secretory proteins that play a role in regulating cell differentiation and cell activity. The regulatory effect of cytokines on the human immune system is particularly important. Cytokines regulate the function of the immune system by affecting the phenotypic differentiation and function of different cells in the immune system. People have noticed the function of cytokines in the immune system a long time ago and tried to apply them to tumor treatment. Interleukin-15 (IL15) is one of the cytokines with anti-tumor potential. IL15 can promote the regeneration and expansion of NK cells and CD8+T cells in the body, and activate their immune function. At the same time, IL15 will not enhance Treg cells that suppress immune function. However, IL15 itself has problems such as a short half-life, and IL15 needs to be artificially modified to become an IL15 superagonist to achieve the best effect.
[0003] At present, many methods can be used to modify IL15 to make it an IL15 superagonist. At present, there are not many reports on this type of drug. For example, the Class 1 new drug FL115 injection reported in 2024 was approved for clinical use by the China National Medical Products Administration (NMPA) and is intended to be developed for the treatment of unresectable locally advanced or metastatic solid tumors. Public information shows that the FL115 injection is an interleukin 15 (IL-15) super immune agonist. IL15 superagonists mainly exist in the form of homologous or heterologous dimers, but on the existing basis, how to construct an IL15 superagonist with strong biological activity is still a task that requires design and screening. Summary of the invention
[0004] Based on this, the purpose of the present invention is to provide an interleukin-15 fusion protein as an IL15 superagonist, which has very strong biological activity and can be used to treat tumors.
[0005] The technical solutions for achieving the above-mentioned purpose include the following.
[0006] An interleukin-15 fusion protein comprises, from N-terminus to C-terminus, CH2 and CH3 segments through an IGHE signal peptide (SP), an IL-15 receptor Rαsushi domain, a connecting peptide 1, an IL-15 functional fragment, a connecting peptide 2 and an Fc monomer, wherein the 72nd amino acid in the IL-15 functional fragment is mutated from N to D, one end of the IL-15 receptor αsushi domain is connected to the IL-15 functional fragment, and the other end of the IL-15 functional fragment is connected to the Fc monomer.
[0007] In some embodiments, the sequence of the IGHE signal peptide is as shown in MDWTWILFLVAAATRVHS (SEQ ID NO: 11).
[0008] In some embodiments, the IL-15 receptor Rα sushi domain is represented by ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPP (SEQ ID NO: 12).
[0009] In some embodiments, the CH2 and CH3 segments of the Fc monomer are as shown in APEFLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTFPPSQEEMTKNQVSLRCLVKGFYPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTFPPSQEEMTKNQVSLRCLVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFRLESRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 13).
[0010] A connecting peptide, which may be a conventional linker sequence for connecting polypeptides, can connect two polypeptides and fold them naturally into a desired structure, and is generally a short peptide having a hydrophobicity and a certain degree of stretchability. The connecting peptide may be flexible, and in some embodiments, a flexible connecting peptide is advantageous, as it can connect two amino acid fragments and maintain their respective activities and functions. In some embodiments, the connecting peptide 1 is shown as ggggsggggsggggsggggs, such as GGGGGGGG, GSLPETGGSRGDGGSL.
[0011] In some embodiments, the connecting peptide 2 is represented by ggggsggggsggggs (SEQ ID NO: 14).
[0012] In some preferred embodiments, the amino acid sequence of the interleukin-15 fusion protein is shown as SEQ ID NO.1.
[0013] The second aspect of the present invention provides the mRNA of the interleukin-15 fusion protein.
[0014] In some embodiments, the mRNA of the interleukin-15 fusion protein is shown as SEQ ID NO.9.
[0015] In some embodiments, the IGHE signal peptide is linked to the IL-15 receptor Rαsushi domain via gs.
[0016] The third aspect of the present invention provides the use of the interleukin-15 fusion protein in the preparation of anti-tumor drugs.
[0017] The fourth aspect of the present invention provides the use of the interleukin-15 fusion protein mRNA in the preparation of anti-tumor drugs.
[0018] The fifth aspect of the present invention provides an anti-tumor drug.
[0019] An anti-tumor drug is prepared from any of the above mRNAs and a nanocarrier for delivering the drug.
[0020] In some embodiments, the nanocarrier is a lipid nanoparticle (LNP).
[0021] In some embodiments, the lipid nanoparticles may include one or more of ionized lipids, PEGylated lipids, cholesterol and derivatives, and neutral auxiliary phospholipids. For example, the lipid nanoparticles may include any one of cationic phospholipids (ionizable lipids), neutral auxiliary phospholipids, cholesterol, polyethylene glycol-modified phospholipids (PEGylated lipid), any combination of any two, any three, or all four.
[0022] In some embodiments, the lipid nanoparticles include SM102 or Dlin-MC3-DMA.
[0023] In some preferred embodiments, the lipid nanoparticle is SM102.
[0024] In some preferred embodiments, the material of the lipid nanoparticles is SM102: DSPC: cholesterol: DMG-PEG2000 in a mass ratio of 50±2: 10±1: 38.5±1: 1.5±0.1.
[0025] In some embodiments, the tumor is a solid tumor.
[0026] A method for treating tumors, comprising administering to a subject an effective dose of any one of the interleukin-15 fusion proteins or the anti-tumor drug containing the mRN of the interleukin-15 fusion protein.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] The present invention optimizes the protein composition of interleukin 15 fusion protein as IL15 superagonist, namely RLI-mono-hFc, to achieve stronger biological activity and has a significant effect of inhibiting tumor growth. The RLI-mono-hFc can be well used for treating tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 . Schematic diagram of the results of comparing the biological activities of RLI-mono-hFc protein and recombinant human IL15 protein.
[0030] Figure 2 .Statistical chart of IL15 superagonist biological activity detection.
[0031] Figure 3 .Statistical graph of tumor volume changes after drug administration in mice.
[0032] Figure 4 .Statistical graph of tumor weight in mice after drug administration.
[0033] Figure 5 .Image record of mouse tumors.
[0034] Figure 6 . Protein electrophoresis of RLI-mono-hFc IL15 superagonist. DETAILED DESCRIPTION
[0035] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0036] The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions, such as the fourth edition of Molecular Cloning: A Laboratory Manual edited by Green and Sambrook, published in 2013, or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.
[0037] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0038] As used herein, the term "expression" (expression or expressing) refers to the process of transcribing from a DNA template into a polynucleotide (such as transcribed into mRNA or other RNA transcripts) and / or the process by which the transcribed mRNA is subsequently translated into a peptide, polypeptide or protein. Transcripts and encoded polypeptides can be collectively referred to as "gene products" or "gene expression products". As used herein, "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also transcription and translation of one or more nucleic acids in a cloning system or in any other context.
[0039] The terms "drug", "pharmaceutical", "therapeutic agent" or "agent capable of being used for treatment" are used interchangeably and refer to molecules, including nucleotides or protein polypeptides, that impart a beneficial effect when administered to a subject. The beneficial effects include the achievement of a diagnostic determination; improving a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder, or pathological condition; and generally combating a disease, symptom, disorder, or pathological condition.
[0040] As used herein, the term "subject" includes, but is not limited to, various animals, such as mammals, such as bovines, equines, ovines, swine, canines, felines, lagomorphs, rodents (e.g., mice or rats), non-human primates (e.g., macaques or cynomolgus monkeys) or humans. In certain embodiments, the subject (e.g., human) suffers from a disorder (e.g., a disorder caused by a disease-related gene defect).
[0041] The term "effective amount" or "therapeutically effective amount" refers to an amount of an agent sufficient to achieve a beneficial or desired result. The therapeutically effective amount may vary depending on one or more of the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the mode of administration, etc., and can be readily determined by one of ordinary skill in the art.
[0042] As used herein, the term "administering or acting on or inhibiting..." to a subject can occur in vitro, ex vivo, or in vivo.
[0043] The present invention designs an IL15 superagonist, and proves by comparison that the superagonist has the strongest biological activity. The IL15 superagonist can treat tumors. According to the characteristics of IL15, the tumor can be a solid tumor (including a tumor with a tangible mass that can be palpated by clinical examination such as X-ray film, CT scan, B-ultrasound, or palpation).
[0044] In some embodiments of the present invention, IL15, IL15Ra, Fc and linker are fused into one protein in different forms, and the expression and biological activity of different schemes are tested.
[0045] In some embodiments of the invention, the interleukin-15 fusion protein comprises, from the N-terminus to the C-terminus, CH2 and CH3 segments through an IGHE signal peptide (signal peptide, SP), an IL-15 receptor Rαsushi domain, a connecting peptide 1, an IL-15 functional fragment, a connecting peptide 2 and an Fc monomer, wherein the amino acid at position 72 in the IL-15 functional fragment is mutated from N to D, one end of the IL-15 receptor αsushi domain is connected to the IL-15 functional fragment, and the other end of the IL-15 functional fragment is connected to the Fc monomer.
[0046] The present invention prepares and purifies the protein of RLI-mono-hFc, and compares the biological activity with that of recombinant human IL15 protein (rhIL-15). The results show that RLI-mono-hFc can induce M07e cell proliferation at a lower concentration. RLI-mono-hFc protein has much higher biological activity than recombinant human IL15.
[0047] The interleukin-15 fusion protein sequence involved in the present invention has the following structure.
[0048] Table 1: Sequence Listing
[0049]
[0050]
[0051]
[0052]
[0053] The present invention is further described in detail below with reference to specific embodiments.
[0054] Example 1
[0055] 1. IL15 superagonist protein composition and experiments
[0056] 1. IL15 superagonist protein composition
[0057] This example provides the amino acid composition of IL15 superagonist (interleukin 15 fusion protein), and the different IL15 superagonist structures are shown in Table 2. For the corresponding sequences of different example groups in Table 2, please refer to the corresponding sequences in Table 1.
[0058] Table 2. Different IL15 superagonist structural schemes for comparison
[0059]
[0060]
[0061] 2 Test the effects of different linkers on the expression and biological activity of RLI-mono-hFc.
[0062] The present invention tests the effects of different linkers connecting various structures of RLI-mono-hFc, indicating that the linker has a low effect on the biological activity of RLI-mono-hFc.
[0063] Table 3. Linkers for IL15 superagonists
[0064] SeqIDNo. Linker Sequence (R-linker2-I-mono-hFc) GGGGGGGG 10(R-linker3-I--mono-hFc) GSLPETGGSRGDGGSL
[0065] 3. Testing the ability of RLI-mono-hFc to inhibit tumors
[0066] The present invention tests the ability of IL15 superagonists to treat tumors. Tumor cells are injected intravenously into mice into the right rear fat pad of mice to produce a mouse subcutaneous colon cancer tumor model. Then, the mRNA / LNP of the IL15 superagonist is injected into the mouse body, and the expression of the IL15 superagonist is detected to prove that the mRNA of the IL15 superagonist can be expressed in vivo. Then, the changes of IL15 on immune-related cells, such as T cells and NK cells, are detected. Finally, the present invention studies the effect of IL15 superagonists in inhibiting the growth of subcutaneous colon cancer tumors in mice.
[0067] The interleukin-15 fusion protein mRNA of the present invention is prepared by in vitro transcription (IVT) method, and is used for structure and sequence screening of IL15 superagonists after capping and purification.
[0068] 3.1 Preparation of mRNA by in vitro transcription
[0069] 3.1.1 Preparation of linearized template
[0070] The plasmid for in vitro transcription was prepared by GenScript Biotech Co., Ltd. The plasmid with the candidate sequence was digested with BspQ1 enzyme, and the digestion system is shown in Table 1:
[0071] Table 1 Enzyme digestion system
[0072] Plasmids 10 μg Buffer 20μl BspQ1 enzyme 10μl RNAfree water To 200 μl
[0073] Incubate at 50℃ for 2-3h.
[0074] 3.1.2 Linearized template purification
[0075] (1) Add 200 μl of DNA purification magnetic beads, mix well, and incubate at room temperature for 10 minutes.
[0076] (2) Place the sample on a magnetic rack for 5 minutes and discard the supernatant.
[0077] (3) Add 200 μl of 80% ethanol and incubate at room temperature for 30 seconds.
[0078] (4) Incubate on the magnetic stand for 5 minutes, discard the supernatant, and repeat twice.
[0079] (5) Aspirate the ethanol and let it air dry at room temperature for 10 minutes. Add 100 μl of Nuclease water, vortex to mix the magnetic beads, incubate at room temperature for 5 minutes, and place on a magnetic stand for 5 minutes.
[0080] (6) Aspirate the supernatant and keep it, then measure the concentration.
[0081] 3.1.3 In vitro transcription
[0082] (1) Vortex and mix all components except T7 RNA Polymerase Mix, centrifuge briefly to collect the components at the bottom of the tube, store on ice until needed, and prepare the system according to Table 2.
[0083] Table 2 In vitro transcription reaction system
[0084] Components volume T7RNAPolymeraseMix 2μl 10xTranscriptionBuffer 2μl N-Me-PseudoUTPSolution 2μl ATPSolution 2μl CTPSolution 2μl GTPSolution 2μl Template 5μl(500ng) <![CDATA[RNase-freeddH20]]> Up to 20 μl
[0085] Add 1 μl RNase inhibitor to 20 μl system.
[0086] (2) Mix the components gently with a pipette, collect by brief centrifugation, and incubate at 37°C for 2 h.
[0087] (3) Add 1 μl of DNase I to the reaction system and incubate at 37°C for 15 min to digest the transcribed DNA template.
[0088] (4) Purification: Purify the RNA using the conventional linearized template and use VAHTS RNA Clean Beads.
[0089] 3.1.4 RNA capping and purification
[0090] (1) Take 50 μg RNA into a 1.5 ml centrifuge tube and dilute it to 65% using RNase-Free ddH20.
[0091] μl, heated at 65°C for 5 min.
[0092] (2) Place the heated centrifuge tube on ice for 5 minutes.
[0093] (3) Add the components as shown in Table 3:
[0094] Table 3 RNA capping and purification reaction system
[0095]
[0096]
[0097] Add 1 μl RNase inhibitor to 20 μl system and incubate at 37°C for 1 h.
[0098] (4) Conventional purification method requires purification using VAHTS RNA Clean Beads.
[0099] 3.2 Preparation of mRNA / LNP
[0100] 3.2.1 Dissolve the prepared mRNA on ice and dilute it to 100 ng / μl with 50 mM sodium citrate buffer as the aqueous phase; prepare the ethanol phase using anhydrous ethanol as the solvent, and prepare it according to the ratio of SM102 (or Dlin-MC3-DMA): DSPC: cholesterol: DMG-PEG2000 = 50:10:38.5:1.5, so that the concentration of SM102 in the ethanol phase is 5.62 mg / ml and the total liposome concentration is 10.28 mg / ml;
[0101] 3.2.2 The aqueous phase and the ethanol phase were coated with a nano-drug preparation system (INano L, Maianna (Shanghai) Instrument Technology Co., Ltd.) at a flow rate ratio of 3:1, and a total flow rate of 12 mL / min, and LNP was collected. The collected LNP was diluted 3 times with RNase-free water and placed in a 100 kd dialysis bag, and then the dialysis bag was placed in 1X PBS with 200 times the volume of LNP for dialysis, with a magnetic stirrer at 300 rpm and room temperature for 18 hours; the LNP collected in the dialysis bag was sterilized and filtered using a 0.22 um filter membrane; the filtered LNP was centrifuged for 90 minutes using a 100 kd ultrafiltration tube at 3000 rpm and 4°C, and the LNP in the ultrafiltration tube was collected, and the residual LNP in the tube was rinsed with 1X PBS, and the mRNA / LNP was obtained after mixing with the previous LNP, and stored at 2-8°C in the dark.
[0102] Second, the test also includes the following experiments:
[0103] 1. Electrophoresis
[0104] 1. Run gel: Remove the seal of 4-12% Bis-Tris Gel and place it in the electrophoresis tank. Add sufficient 1xSDS Running Buffer and rinse the channels 3 times with Running Buffer. After rinsing, load samples in the following order, 20ul for each sample. Connect to the electrophoresis instrument electrode, adjust the constant voltage to 200v, and run for about 40min.
[0105] 2. Transfer: ① Cut the PVDF membrane according to the size of the gel, and make a notch in the upper right corner as a direction mark, and soak the membrane in methanol for 30 minutes. ② Transfer: After the electrophoresis is completed, remove the gel from the gel plate, soak it in the transfer solution, install the transfer splint in the order of sponge-2 layers of filter paper-gel-PVDF membrane-2 layers of filter paper-sponge, and put the transfer splint into the electrophoresis tank filled with transfer solution. Connect the electrophoresis instrument and transfer for 80 minutes at a constant voltage of 90V.
[0106] 3. Blocking: Take out the membrane and place it in an incubation box containing 10 ml of 5% skimmed milk powder, place it on a shaker at 80 rpm, and incubate at room temperature for 1 hour.
[0107] 4. Wash the membrane: Recover the milk and store at 4°C. Wash the membrane 3 times with 1x TBST, shaking at 130 rpm for 10 min each time.
[0108] 6. Incubate with primary antibody: Prepare IL-15 antibody according to the recommended dilution (20ul antibody + 10ml TBST), place the membrane in the incubation box containing the antibody, incubate on a shaker at 80rpm, at room temperature for 1h, and incubate overnight at 4℃.
[0109] 7. Wash the membrane: Recover the primary antibody incubated yesterday and store at -20°C. Wash the membrane 3 times with TBST, shaking at 130 rpm for 10 min each time.
[0110] 2. Incubate with secondary antibody: 2ul goat anti-rabbit IgG / horseradish enzyme labeled + 10ml 0.5% skim milk powder. Pour out TBST and add 10ml secondary antibody solution. Incubate at room temperature for 1h on a shaker at 80rpm.
[0111] 3. Wash the membrane: Recover the secondary antibody and store at -20°C. Wash the membrane 3 times with TBST, 130 rpm, 10 min each time.
[0112] 4. Development (avoid light): Use ECL luminescent liquid to expose the effect of the film.
[0113] 2. IL15 superagonist biological activity detection
[0114] 1. Cell starvation treatment: Take M07e cells in the logarithmic growth phase, centrifuge at 1000rpm for 5 minutes, discard the supernatant and wash twice with PBS, resuspend in 1640 cytokine-free medium containing 20% serum (10ml serum added to 40ml 1640 basal medium), take 20ul of cell suspension, add 20ul AOPI dye solution and mix well, add cell counting plate and insert cell counter to count: record the live cell density and cell viability. Take excess cell suspension according to the live cell concentration and starve it in a CO2 constant temperature incubator for 4h.
[0115] 2. Prepare mRNA suitable for transfection, transfect 1 ug per well (n=3), and set up a culture medium control without cytokines.
[0116] 3. Cell plating: After starvation treatment, centrifuge the cells at 1000rpm for 5 minutes, discard the supernatant, and resuspend them in Opti-MEM medium. Take 20ul of cell suspension and add 20ul of AOPI dye solution to mix evenly, then add the cell counting plate and insert the cell counter to count: record the live cell density and cell viability. Take the corresponding volume of cell suspension according to the live cell density, add the appropriate amount of Opti-MEM medium to make 4ml3x10 5cells / ml cell suspension. Because the proliferation assay requires the determination of luminescence values, and there will be signal interference between adjacent wells of the transparent culture plate, the transparent plate is plated with separate wells, and 50ul of cell suspension (i.e., 1.5x104 cells / well) or opti-MEM culture medium (negative control) is added to each well. Except for the negative control wells, 1ug of mRNA is transfected into each well (n=3). Because the culture plate has a marginal volatile effect, 100ul of PBS is added to the outermost circle of culture wells. The plated cells are placed in a CO2 constant temperature incubator and cultured statically for 24 / 48h.
[0117] 4. Cell viability detection: Take out the cell culture plate and equilibrate it at room temperature for 10 minutes (usually not more than 30 minutes), add 100ul CellTiter-Lumi TM Plus luminescence detection reagent, shake at room temperature for 2 minutes to promote cell lysis. Then incubate for 10 minutes to allow the luminescence signal to stabilize. Use a multi-function microplate reader for chemiluminescence detection.
[0118] 3. Subcutaneous Colon Cancer (CT26) Tumor Model
[0119] The tumor cells were washed twice with PBS and the cell concentration was adjusted to 5 × 10 6 / mL, subcutaneously injected into the right rear fat pad of mice, 100 μL / mouse, i.e. 5×10 5 / mice.
[0120] The specific steps include: inoculating CT26 cells into the right posterior fat pad of 50 female BALB / c mice, and waiting for the tumor to grow to 20-40 mm 3 At 14:00, mice were divided into groups and administered according to tumor volume, and the day of administration was recorded as Day 0. The control group was injected with PBS, and the other two groups were injected with 5 μg or 10 μg of mRNA / LNP expressing RLI-mono-hFc. There were 8 mice in each group. During the experiment, the weight and tumor volume of the mice were recorded. At the end of the experiment, the tumor-bearing mice were euthanized, and the tumors of the mice were weighed and photographed for record.
[0121] 3. Experimental Results
[0122] 1. Characteristics of RLI-mono-hFc IL15 superagonist protein
[0123] if Figure 6 As shown, RLI-mono-hFc IL15 superagonist is a protein with a molecular weight of about 70 kd. The mRNA of SEQ ID NO.9 was transfected into A375 cells, and the supernatant was taken after 24 hours to detect the secreted RLI-mono-hFc IL15 superagonist. The transfection method and electrophoresis method are as described in the above-mentioned "IL15 superagonist biological activity detection" and "electrophoresis" methods.
[0124] The protein structure will affect its expression and work. The present invention will compare the designed IL15 superagonist structure (RLI-mono-hFc) with IL15 superagonist candidates of other structures to prove that it has advantages in expression and biological activity (Table 1). M07e is a megakaryocyte cell line that responds to IL15 stimulation and proliferates. The ability of IL15 superagonist to stimulate M07e proliferation is an indicator of the function of IL15 superagonist. At present, the IL15 superagonist of the present invention is much higher in biological activity than wild-type IL15 ( Figure 1 ). Different amounts of RLI-mono-hFc and commercially purchased recombinant human IL15 (rhIL15) were added to the M07e culture medium, and the cell viability (i.e., the number of live cells) was detected after 48 hours to compare the biological activity of RLI-mono-hFc IL15 superagonist and wild-type human IL15. The results showed that the EC50 of RLI-mono-hFc was much lower than that of wild-type human IL15 (0.48 vs. 3.37), reflecting a significant improvement in biological activity. IL15 has a recognized ability to promote the proliferation of T cells and NK cells, both of which are immune cells directly involved in killing tumor cells; IL15 plays an important role in tumor suppression, and the IL15 superagonist RLI-mono-hFc, whose biological activity far exceeds that of wild-type IL-15, has a strong anti-tumor potential.
[0125] 2. IL15 superagonist biological activity detection
[0126] By fusing IL15, IL15Ra, Fc and linker in different forms into one protein, their biological activities were compared and the effects of different linkers on the biological activity of RLI-mono-hFc were tested.
[0127] The mRNA suitable for transfection was prepared by in vitro transcription (IVT) and incubated with Mo7e cells for 24 h to detect the cell viability (i.e., the number of living cells) and compare the biological activity. Figure 2 As shown, RLI-mono-hFc has the highest cell viability, which proves that the biological activity of RLI-mono-hFc described in the present invention is superior to that of IL15 superagonists composed of other sequences. Figure 2As can be seen, the biological activity of RLI-mono-hFc is stronger than that of ILR-mono-hFc, suggesting that the IL-15 receptor Rαsushi domain placed in front of the IL15 functional fragment is more beneficial to the IL15 superagonist function. The biological activity of RLI-mono-hFc is also stronger than that of mono-hFc-RLI and mono-hFc-ILR, suggesting that hFc placed in front is not beneficial to the function of IL15. The two tested linkers, linker2 and linker3, as components of the fusion protein (other components are the same as RLI-mono-hFc), also have good biological activity of the IL15 fusion protein, but not as good as linker1, suggesting that linker1 is the most beneficial to the fusion protein.
[0128] 3. Observation of the tumor inhibition effect of RLI-mono-hFc
[0129] By constructing a mouse subcutaneous colon cancer (CT26) tumor model, the tumor inhibition effect of different doses of RLI-mono-hFc in the BALB / c mouse CT26 subcutaneous tumor model was observed. Figure 3 ), compared with the PBS control group, RLI-mono-hFc (5ug) and RLI-mono-hFc (10ug) inhibited the growth of mouse colon cancer (CT26) tumors. Compared with the control group, RLI-mono-hFc (5ug) tumor growth inhibition rate (TGI TV ) was 55.23%, and the tumor growth inhibition rate (TGI TV ) was 88.89%. Compared with the control group, RLI-mono-hFc (10ug) had a significant inhibitory effect on tumor growth.
[0130] From the statistical results of tumor weight ( Figure 4 ), compared with the control group, RLI-mono-hFc (5ug) tumor growth inhibition rate (TGI Tw ) was 47.51%, and the tumor growth inhibition rate (TGI Tw ) is 86.48%. According to the tumor record results ( Figure 5 ), two mice (1 / 4) in the RLI-mono-hFc (5ug) group had tumor regression, and five mice (5 / 8) in the RLI-mono-hFc (10ug) group had tumor regression. From the above experimental results, it can be seen that the IL15 superagonist RLI-mono-hFc of the present invention effectively inhibits the growth of mouse colon cancer (CT26). The IL15 superagonist RLI-mono-hFc can be used for the treatment of tumors.
[0131] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. An interleukin-15 fusion protein, characterized in that: From the N-terminus to the C-terminus, it includes, in sequence, the CH2 and CH3 segments of the IGHE signal peptide, the IL-15 receptor Rαsushi domain, the connecting peptide 1, the IL-15 functional fragment, the connecting peptide 2 and the Fc monomer, wherein the amino acid at position 72 in the IL-15 functional fragment is mutated from N to D.
2. The interleukin-15 fusion protein according to claim 1, characterized in that: The sequence of the IGHE signal peptide is shown in SEQ ID NO:
11.
3. The interleukin-15 fusion protein according to claim 1, characterized in that: The IL-15 receptor Rαsushi domain is shown in SEQ ID NO:
12.
4. The interleukin-15 fusion protein according to claim 1, characterized in that: The CH2 and CH3 segments of the Fc monomer are shown in SEQ ID NO:
13.
5. The interleukin-15 fusion protein according to any one of claims 1 to 4, characterized in that: The connecting peptide 1 and the connecting peptide 2 are shown in SEQ ID NO:
14.
6. The interleukin-15 fusion protein according to any one of claims 1 to 4, characterized in that: The amino acid sequence of the interleukin-15 fusion protein is shown in SEQ ID NO.
1.
7. The mRNA of the interleukin-15 fusion protein according to any one of claims 1 to 6.
8. The mRNA according to claim 7, which is shown in SEQ ID NO.
9.
9. Use of the interleukin-15 fusion protein according to any one of claims 1 to 6 in the preparation of anti-tumor drugs.
10. Use of the interleukin-15 fusion protein mRNA according to any one of claims 1 to 6 in the preparation of anti-tumor drugs.
11. An anti-tumor drug, wherein: The anti-tumor drug is prepared from the mRNA according to claim 7 or 8 and a nanocarrier for delivering the drug.
12. The anti-tumor drug according to claim 11, wherein The nanocarrier is a lipid nanoparticle.
